Skip to main content

and
  1. Article

    Open Access

    Combined treatment using adoptive cell therapy, extended pharmacokinetic IL-2, and tumor-specific antibodies leads to cures of established B16F10 tumors and extended in vivo T cell survival

    Cary F Opel, K Dane Wittrup in Journal for ImmunoTherapy of Cancer (2013)